Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MET alterations in advanced non-small cell lung cancer.

Current problems in cancer - 1 Apr 2024

Chagas Gabriel Cavalcante Lima, Rangel Amanda Ribeiro, El Osta Badi

Abstract excerpt

Precision medicine has helped identify several tumor molecular aberrations to be treated with targeted therapies. These therapies showed substantial improvement in efficacy without excessive toxicity in patients with specific oncogenic drivers with advanced cancers. In metastatic lung cancers, the implementation of broad platforms for molecular tumor sequencing has helped oncology providers identify oncogenic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Precision Medicine

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Source

Identifiers

PMID: 38480027
DOI: 10.1016/j.currproblcancer.2024.101075

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MET alterations in advanced non-small cell lung cancer.PMID 38480027Read ↗

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?Semantic proximity Read ↗

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.Semantic proximity Read ↗

MET alterations in advanced non-small cell lung cancer.Semantic proximity Read ↗

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alterationSemantic proximity Read ↗

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

MET alterations in NSCLC-Current Perspectives and Future Challenges.Semantic proximity Read ↗

Targeting un-MET needs in advanced non-small cell lung cancer.Semantic proximity Read ↗

Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.Semantic proximity Read ↗

Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.Semantic proximity Read ↗

MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.Semantic proximity Read ↗

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.Semantic proximity Read ↗

KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.